Boundless Bio Appoints Jessica Oien as General Counsel and Corporate Secretary

Boundless Bio Appoints Jessica Oien as General Counsel and Corporate Secretary




Boundless Bio Appoints Jessica Oien as General Counsel and Corporate Secretary

-Ms. Oien is a senior biotech executive with more than 20 years serving as legal counsel to private and public biotechnology companies-

SAN DIEGO–(BUSINESS WIRE)–Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced that it has appointed Jessica Oien as General Counsel and Corporate Secretary.

“It is my pleasure to welcome Jessica to our management team as General Counsel and Corporate Secretary,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. “Jessica has extensive practice growing biotech businesses throughout her career. Her significant experience advising Boards and executive teams will be instrumental for Boundless as we continue into our next stages of growth and advance into the clinic.”

Ms. Oien joins Boundless Bio after serving as General Counsel and Corporate Secretary at the public biotechnology company Cidara Therapeutics. Prior to Cidara, Ms. Oien served in various senior legal roles of increasing responsibility at Otonomy, Inc., Pernix Therapeutics, Somaxon Pharmaceuticals, Verus Pharmaceuticals, and Elan Corporation. Additionally for the past decade, Ms. Oien has also provided legal consulting services for early-stage biotech companies, advising numerous collaborations and other research and development programs. Jessica began her legal career as a corporate associate at Brobeck, Phleger & Harrison and Milbank, Tweed, Hadley & McCloy.

Ms. Oien received her J.D. from Loyola Law School and a B.A. in Economics and Political Science from North Dakota State University.

“It’s an honor to be a part of Boundless Bio’s mission to bring transformative medicine to patients with oncogene amplified cancers,” said Ms. Oien. “The team has made significant progress in developing this emerging field of cancer biology and a pipeline of therapies directed against ecDNA. I’m thrilled to join the company at this exciting time.”

About Boundless Bio

Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and Twitter.

Contacts

James Lee

Director of Business Development

Boundless Bio

jlee@boundlessbio.com